Role of HLA in Hematopoietic Stem Cell Transplantation

Meerim Park, Jong Jin Seo, Meerim Park, Jong Jin Seo

Abstract

The selection of hematopoietic stem cell transplantation (HSCT) donors includes a rigorous assessment of the availability and human leukocyte antigen (HLA) match status of donors. HLA plays a critical role in HSCT, but its involvement in HSCT is constantly in flux because of changing technologies and variations in clinical transplantation results. The increased availability of HSCT through the use of HLA-mismatched related and unrelated donors is feasible with a more complete understanding of permissible HLA mismatches and the role of killer-cell immunoglobulin-like receptor (KIR) genes in HSCT. The influence of nongenetic factors on the tolerability of HLA mismatching has recently become evident, demonstrating a need for the integration of both genetic and nongenetic variables in donor selection.

References

    1. Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235–2241.
    1. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576–4583.
    1. Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens. 2012;80(1):1–11.
    1. Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens. 2005;65(4):301–369.
    1. Parham P. Histocompatibility typing—Mac is back in town. Immunology Today. 1988;9(5):127–130.
    1. Argüello JR, Madrigal JA. HLA typing by Reference Strand Mediated Conformation Analysis (RSCA) Reviews in immunogenetics. 1999;1(2):209–219.
    1. Argüellol JR, Little AM, Pay AL, et al. Mutation detection and typing of polymorphic loci through double-strand conformation analysis. Nature Genetics. 1998;18(2):192–194.
    1. Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. British Journal of Haematology. 2010;150(3):251–258.
    1. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French society of bone marrow transplantation and cell therapy. Journal of Clinical Oncology. 2006;24(36):5695–5702.
    1. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200–4206.
    1. Park M, Koh KN, Kim BE, et al. The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children. Korean Journal of Hematology. 2011;46(1):11–17.
    1. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. New England Journal of Medicine. 2001;345(25):1794–1800.
    1. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92(10):3515–3520.
    1. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923–1930.
    1. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. New England Journal of Medicine. 1998;339(17):1177–1185.
    1. Petersdorf EW, Kollman C, Hurley CK, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program experience. Blood. 2001;98(10):2922–2929.
    1. Petersdorf EW, Gooley T, Malkki M, Horowitz M. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007;69(supplement 1):25–30.
    1. Morishima Y, Kawase T, Malkki M, Petersdorf EW. Effect of HLA-A2 allele disparity on clinical outcome in hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007;69(supplement 1):31–35.
    1. Fleischhauer K, Zino E, Mazzi B, et al. Peripheral blood stem cell allograft rejection mediated by CD4+ T lymphocytes recognizing a single mismatch at HLA-DPβ1∗0901. Blood. 2001;98(4):1122–1126.
    1. Zino E, Frumento G, Marktel S, et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood. 2004;103(4):1417–1424.
    1. Crocchiolo R, Zino E, Vago L, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood. 2009;114(7):1437–1444.
    1. Petersdorf EW, Gooley T, Malkki M, et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. British Journal of Haematology. 2001;112(4):988–994.
    1. Gallardo D, Brunet S, Torres A, et al. HLA-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease. Transplantation. 2004;77(7):1107–1110.
    1. Schaffer M, Aldener-Cannavá A, Remberger M, Ringdén O, Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens. 2003;62(3):243–250.
    1. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104(9):2976–2980.
    1. Greinix HT, Faé I, Schneider B, et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplantation. 2005;35(1):57–62.
    1. Liao C, Wu JY, Xu ZP, et al. Indiscernible benefit of high-resolution HLA typing in improving long-term clinical outcome of unrelated umbilical cord blood transplant. Bone Marrow Transplantation. 2007;40(3):201–208.
    1. Heemskerk MBA, Cornelissen JJ, Roelen DL, et al. Highly diverged MHC class I mismatches are acceptable for haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2007;40(3):193–200.
    1. Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood. 2001;98(10):3150–3155.
    1. Teshima T, Matsuo K, Matsue K, et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. British Journal of Haematology. 2005;130(4):575–587.
    1. Shaw BE, Russell NH, Devereux S, et al. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica. 2005;90(11):1562–1569.
    1. Mead AJ, Thomson KJ, Morris EC, et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood. 2010;115(25):5147–5153.
    1. Crocchiolo R, Ciceri F, Fleischhauer K, et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplantation. 2009;44(9):571–577.
    1. Claas FH. Clinical relevance of circulating donor-specific HLA antibodies. Current Opinion in Organ Transplantation. 2010;15(4):462–466.
    1. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contributions to Nephrology. 2009;162:1–12.
    1. Van Den Berg-Loonen EM, Billen EVA, Voorter CEM, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008;85(8):1086–1090.
    1. Storb R. B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients. Blood. 2009;113(5):p. 1205.
    1. Gabbianelli M, Boccoli G, Petti S, et al. Expression and in-vitro modulation of HLA antigens in ontogenic development of human hemopoietic system. Annals of the New York Academy of Sciences. 1987;511:138–147.
    1. Terasaki PI, Mickey MR, Singal DP, Mittal KK, Patel R. Serotyping for homotransplantation. XX. Selection of recipients for cadaver donor transplants. New England Journal of Medicine. 1968;279(20):1101–1103.
    1. Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115(13):2704–2708.
    1. Ciurea SO, De Lima M, Cano P, et al. High risk of graft failure in patients with anti-hla antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88(8):1019–1024.
    1. Focosi D, Zucca A, Scatena F. The role of anti-HLA antibodies in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2011;17(11):1585–1588.
    1. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Current Opinion in Immunology. 2004;16(5):626–633.
    1. Parham P. MHC class I molecules and KIRS in human history, health and survival. Nature Reviews Immunology. 2005;5(3):201–214.
    1. Cook MA, Milligan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103(4):1521–1526.
    1. Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. British Journal of Haematology. 2003;123(2):323–326.
    1. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biology of Blood and Marrow Transplantation. 2006;12(8):876–884.
    1. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814–819.
    1. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726–732.
    1. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411–2419.
    1. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell aloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100.
    1. Clausen J, Wolf D, Petzer AL, et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clinical and Experimental Immunology. 2007;148(3):520–528.
    1. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009;23(3):492–500.
    1. Pegram HJ, Ritchie DS, Smyth MJ, et al. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leukemia Research. 2011;35(1):14–21.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner